About us Contacts Drug interactions: 390 212
Drug search by name

Filgrastim-aafi and Polatuzumab Vedotin-piiq

Determining the interaction of Filgrastim-aafi and Polatuzumab Vedotin-piiq and the possibility of their joint administration.

Check result:
Filgrastim-aafi <> Polatuzumab Vedotin-piiq
Relevance: 21.11.2022 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Consumer information for this interaction is not currently available.ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells. MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents. References "Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA. "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA. "Product Information. Stemgen (ancestim)" Amgen, Thousand Oaks, CA. "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA. View all 4 references

Professional:

ADJUST DOSING INTERVAL: The safety and efficacy of hematopoietic growth factors such as colony-stimulating factors (G-CSF and GM-CSF) and stem cell factors (SCF) given simultaneously with cancer chemotherapy have not been established. Theoretical concerns exist regarding their concomitant administration because hematopoietic growth factors stimulate myeloid cell proliferation while antineoplastic agents primarily target rapidly dividing cells.

MANAGEMENT: Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, hematopoietic growth factors should not be used within 24 hours before or 24 hours after administration of antineoplastic agents.

References
  • "Product Information. Leukine (sargramostim)." Immunex Corporation, Seattle, WA.
  • "Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA, North Wales, PA.
  • "Product Information. Stemgen (ancestim)" Amgen, Thousand Oaks, CA.
  • "Product Information. Neupogen (filgrastim)." Amgen, Thousand Oaks, CA.
Filgrastim-aafi

Generic Name: filgrastim

Brand name: Neupogen, Neupogen SingleJect, Nivestym, Zarxio

Synonyms: Filgrastim

Polatuzumab Vedotin-piiq

Generic Name: polatuzumab vedotin

Brand name: Polivy

Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle